Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Matteo Bassetti, Mari Ariyasu, Bruce Binkowitz, Tsutae Den Nagata, Roger M Echols, Yuko Matsunaga, Kiichiro Toyoizumi & Yohei Doi. (2019) Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study. Infection and Drug Resistance 12, pages 3607-3623.
Read now
Read now
Glenn S Tillotson. (2012) Foreword: 10-year special edition. Expert Review of Anti-infective Therapy 10:11, pages 1219-1220.
Read now
Read now
Articles from other publishers (12)
Luiza Helena Gremski, Fernando Hitomi Matsubara, Nayanne Louise Costacurta Polli, Bruno Cesar Antunes, Pedro Henrique de Caires Schluga, Hanna Câmara da Justa, João Carlos Minozzo, Ana Carolina Martins Wille, Andrea Senff-Ribeiro & Silvio Sanches Veiga. (2021) Prospective Use of Brown Spider Venom Toxins as Therapeutic and Biotechnological Inputs. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Roger Echols, Mari Ariyasu & Tsutae Den Nagata. (2019) Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance. Clinical Infectious Diseases 69:Supplement_7, pages S559-S564.
Crossref
Crossref
George H. Talbot. (2018) Evolution and current status of United States Food and Drug Administration and European Medicines Agency regulatory guidance for studies of nosocomial pneumonia. Current Opinion in Critical Care 24:5, pages 379-384.
Crossref
Crossref
S. Sudarshan & B. L. Dhananjaya. (2016) Antibacterial activity of an acidic phospholipase A2 (NN-XIb-PLA2) from the venom of Naja naja (Indian cobra). SpringerPlus 5:1.
Crossref
Crossref
Shivalingaiah Sudharshan & Bhadrapura Lakkappa Dhananjaya. (2015) Antibacterial potential of a basic phospholipase A2 (VRV-PL-VIIIa) from Daboia russelii pulchella (Russell’s viper) venom. Journal of Venomous Animals and Toxins including Tropical Diseases 21:1.
Crossref
Crossref
S. Sudarshan & B. L. Dhananjaya. (2015) The Antimicrobial Activity of an Acidic Phospholipase A2 (NN-XIa-PLA2) from the Venom of Naja naja naja (Indian Cobra). Applied Biochemistry and Biotechnology 176:7, pages 2027-2038.
Crossref
Crossref
Esther Bettiol, Jeffrey D. Wetherington, Nicola Schmitt & Stephan Harbarth. (2015) Challenges and Solutions for Clinical Development of New Antibacterial Agents: Results of a Survey among Pharmaceutical Industry Professionals. Antimicrobial Agents and Chemotherapy 59:7, pages 3695-3699.
Crossref
Crossref
Brad Spellberg, John Bartlett, Rich Wunderink & David N. Gilbert. (2015) Novel Approaches Are Needed to Develop Tomorrow’s Antibacterial Therapies. American Journal of Respiratory and Critical Care Medicine 191:2, pages 135-140.
Crossref
Crossref
S. Sudarshan & B. L. Dhananjaya. (2014) Antibacterial potential of a basic phospholipase A2 (VRV-PL-V) of Daboia russellii pulchella (Russell’s viper) venom. Biochemistry (Moscow) 79:11, pages 1237-1244.
Crossref
Crossref
Brad Spellberg. (2014) The future of antibiotics. Critical Care 18:3, pages 228.
Crossref
Crossref
Abdullah Balkhair, Yahya M. Al-Farsi, Zakariya Al-Muharrmi, Raiya Al-Rashdi, Mansoor Al-Jabri, Fatma Neilson, Sara S. Al-Adawi, Marah El-Beeli & Samir Al-Adawi. (2014) Epidemiology of Multi-Drug Resistant Organisms in a Teaching Hospital in Oman: A One-Year Hospital-Based Study. The Scientific World Journal 2014, pages 1-6.
Crossref
Crossref
David M. Shlaes, Dan Sahm, Carol Opiela & Brad Spellberg. (2013) The FDA Reboot of Antibiotic Development. Antimicrobial Agents and Chemotherapy 57:10, pages 4605-4607.
Crossref
Crossref